SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma, Inc. is a biopharmaceutical company focused on ophthalmology. It is developing long-acting drug delivery systems for chronic eye diseases.

Its approach pairs sustained-release drug pads with intraocular lenses that are implanted during routine cataract surgery. The pads then release medication inside the eye over an extended period. The lead application is lowering intraocular pressure in patients with glaucoma or ocular hypertension, with the goal of reducing reliance on daily eye drops.

The company's common stock trades on the Nasdaq under the ticker SGP.